Market By Therapeutics & Diagnostics And Geography | Forecast 2019-2027
North America Alzheimer’s disease therapeutics and diagnostics market is expected to rise at a CAGR of 7.58% in terms of revenue during the estimated period of 2019-2027.
The key countries covered in North America Alzheimer’s disease therapeutics and diagnostics market are:
• The United States
• Canada
Alzheimer’s is one of the leading causes of death in the North America region. It is an asymptomatic disease that causes problems like degradation of memory, inability to think properly and erratic behavioral changes. From the treatment context, very few therapeutic alternative techniques are available in the market, and none of them are accurate enough to provide the best-personalized drug diagnostics based on the stage, symptoms and various demographics of the patient. Added to this, the lack of trained professionals and training centers for the diseases indicates an upcoming market demand and a progressive growth potential in these regions for the Alzheimer’s disease therapeutics and diagnostics market.
As the size and proportion of the United States’ population aged 65 and older continue to increase, the number of Alzheimer’s cases are increasing rapidly. ‘Alzheimer’s Initiative’ started by former president Barak Obama in 2011 has shown significant improvements in the drug development and medical services in the US. In Canada, the number of Alzheimer’s cases has been anticipated to increase by xx% by 2031. The high costs of treatments have taken a toll on the common man living in the North American region. But the improvements in the health awareness initiatives, higher education with respect to trained professionals and various research programs are paving the way for a profitable market for the companies operating in the market.
The North America-based Amarantus BioScience Holdings, Inc. is a headquartered in California. It is a biopharmaceutical company involved in developing therapeutic and diagnostic products. The company is focusing on developing and commercializing neurology diagnostic products; it developed “LymPro Test,” which is a blood-based assay for the diagnosis of Alzheimer’s disease. Established in 2008 as Amarantus Bioscience, Inc., the company changed its name to Amarantus BioScience Holdings, Inc. in 2013.
The top key players in the Alzheimer’s disease therapeutics and diagnostics market include AbbVie, Amarantus BioScience Holdings Inc., AXON Neuroscience SE, Baxter, Biogen, Cognoptix, DiaGenic ASA, Roche, GE Healthcare, Merck, Johnson & Johnson, Piramal Enterprises Ltd., Siemens Healthineers AG, and Sun Pharmaceutical Industries Ltd.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCE MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREATS
OF SUBSTITUTE PRODUCT
2.2.3. BARGAINING
POWER OF BUYER
2.2.4. BARGAINING
POWER OF SUPPLIER
2.2.5. INTENSITY
OF COMPETITIVE RIVALRY
2.3. VENDOR
SCORECARD
2.4. ETYMOLOGY
2.5. PARENT
MARKET OUTLOOK
2.6. STRATEGIC
BUYING CRITERIA OUTLOOK
2.7. KEY
FINDINGS
2.8. INDUSTRY
STRUCTURE
2.8.1. RESEARCH
AND DEVELOPMENT
2.8.2. MANUFACTURING
2.8.3. RAW
MATERIALS
2.8.4. END
USER
2.8.5. WHOLESALERS
2.9. REGULATORY
FRAMEWORK
2.10. THE
UNITED STATES AND EUROPE REGULATORY AGENCY
2.11. ALZHEIMER'S
DISEASE ETIOLOGY
2.12. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.13. MARKET
DRIVERS
2.13.1. GROWTH
OF THE ALZHEIMER’S DISEASE
2.13.2. GROWING
GERIATRIC POPULATION
2.13.3. SUBSTANTIAL
INVESTMENTS BY GOVERNMENT IN RESEARCH
2.14. MARKET
RESTRAINTS
2.14.1. STRINGENT
GOVERNMENT REGULATIONS
2.14.2. THE
TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH
2.15. MARKET
OPPORTUNITIES
2.15.1. IN-VITRO
DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET
2.15.2. R&D
INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING
2.16. MARKET
CHALLENGES
2.16.1. AWARENESS
IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE
2.16.2. VERY
FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE
3. ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND
DIAGNOSTICS
3.1. THERAPEUTICS
3.1.1. THERAPEUTICS
BY DRUGS
3.1.1.1. MARKETED
DRUGS
3.1.1.2. PIPELINE
DRUGS
3.1.2. THERAPEUTICS
BY DISEASE STAGE
3.1.2.1. LATE
STAGE: SEVERE AD
3.1.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.1.3. PRODROMAL
STAGE
3.1.4. THERAPEUTICS
BY GENERIC AND BRANDED
3.1.4.1. BRANDED
3.1.4.2. GENERIC
3.2. DIAGNOSTIC
TYPE
3.2.1. LUMBAR
PUNCTURE TEST
3.2.2. POSITRON
EMISSION TOMOGRAPHY
3.2.3. ELECTROENCEPHALOGRAPHY
3.2.4. MAGNETIC
RESONANCE IMAGING
3.2.5. COMPUTED
TOMOGRAPHY
3.2.6. OTHER
DIAGNOSTICS
4. ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – NORTH AMERICA
4.1. MARKET
BY THERAPEUTICS AND DIAGNOSTICS
4.2. COUNTRY
ANALYSIS
4.2.1. THE
UNITED STATES
4.2.2. CANADA
5. COMPANY
PROFILES
5.1. ABBVIE
5.2. AMARANTUS
BIOSCIENCE HOLDINGS, INC.
5.3. AXON
NEUROSCIENCE SE
5.4. BAXTER
5.5. BIOGEN
5.6. COGNOPTIX
5.7. DIAGENIC
ASA
5.8. ROCHE
5.9. GE
HEALTHCARE
5.10. MERCK
5.11. JOHNSON
& JOHNSON
5.12. PIRAMAL
ENTERPRISES LTD.
5.13. SIEMENS
HEALTHINEERS AG
5.14. SUN
PHARMACEUTICAL INDUSTRIES LTD.
6. RESEARCH
METHODOLOGY & SCOPE
6.1. RESEARCH
SCOPE & DELIVERABLES
6.1.1. OBJECTIVES
OF STUDY
6.1.2. SCOPE
OF STUDY
6.2. SOURCES
OF DATA
6.2.1. PRIMARY
DATA SOURCES
6.2.2. SECONDARY
DATA SOURCES
6.3. RESEARCH
METHODOLOGY
6.3.1. EVALUATION
OF PROPOSED MARKET
6.3.2. IDENTIFICATION
OF DATA SOURCES
6.3.3. ASSESSMENT
OF MARKET DETERMINANTS
6.3.4. DATA
COLLECTION
6.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 2 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($
MILLION)
TABLE 3 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($
MILLION)
TABLE 4 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED
2019-2027 ($ MILLION)
TABLE 5 NORTH AMERICA ALZHEIMER’S DISEASE
DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027
($ MILLION)
TABLE 7 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE 1 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 2 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)
FIGURE 3 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)
FIGURE 4 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)
FIGURE 5 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)
FIGURE 6 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($
MILLION)
FIGURE 7 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)
FIGURE 8 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS MARKET IN BRANDED 2019-2027 ($ MILLION)
FIGURE 9 NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS
MARKET IN GENERIC 2019-2027 ($ MILLION)
FIGURE 10 NORTH AMERICA ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)
FIGURE 11 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)
FIGURE 12 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 13 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)
FIGURE 14 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)
FIGURE 15 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 16 NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS
MARKET IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)
FIGURE 17 THE UNITED STATES ALZHEIMER’S DISEASE
THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
FIGURE 18 CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND
DIAGNOSTICS MARKET 2019-2027 ($ MILLION)